Invizyne Technologies (IZTC) Competitors $9.90 +0.09 (+0.89%) As of 07/15/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock IZTC vs. IMMP, FENC, EDIT, SOPH, MNPR, ESPR, PRQR, SLRN, CGC, and TVGNShould you be buying Invizyne Technologies stock or one of its competitors? The main competitors of Invizyne Technologies include Prima BioMed (IMMP), Adherex Technologies (FENC), Editas Medicine (EDIT), SOPHiA GENETICS (SOPH), Monopar Therapeutics (MNPR), Esperion Therapeutics (ESPR), ProQR Therapeutics (PRQR), Acelyrin (SLRN), Canopy Growth (CGC), and Semper Paratus Acquisition (TVGN). These companies are all part of the "pharmaceutical products" industry. Invizyne Technologies vs. Its Competitors Prima BioMed Adherex Technologies Editas Medicine SOPHiA GENETICS Monopar Therapeutics Esperion Therapeutics ProQR Therapeutics Acelyrin Canopy Growth Semper Paratus Acquisition Prima BioMed (NASDAQ:IMMP) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends. Is IMMP or IZTC more profitable? Company Net Margins Return on Equity Return on Assets Prima BioMedN/A N/A N/A Invizyne Technologies N/A N/A N/A Does the media prefer IMMP or IZTC? In the previous week, Prima BioMed had 1 more articles in the media than Invizyne Technologies. MarketBeat recorded 1 mentions for Prima BioMed and 0 mentions for Invizyne Technologies. Prima BioMed's average media sentiment score of 1.87 beat Invizyne Technologies' score of 0.00 indicating that Prima BioMed is being referred to more favorably in the media. Company Overall Sentiment Prima BioMed Very Positive Invizyne Technologies Neutral Do analysts prefer IMMP or IZTC? Prima BioMed presently has a consensus target price of $7.00, indicating a potential upside of 326.83%. Given Prima BioMed's stronger consensus rating and higher probable upside, equities research analysts plainly believe Prima BioMed is more favorable than Invizyne Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prima BioMed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders believe in IMMP or IZTC? 2.3% of Prima BioMed shares are owned by institutional investors. 3.1% of Prima BioMed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has better earnings & valuation, IMMP or IZTC? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrima BioMedN/AN/A-$28.01MN/AN/AInvizyne TechnologiesN/AN/AN/AN/AN/A SummaryPrima BioMed beats Invizyne Technologies on 7 of the 7 factors compared between the two stocks. Get Invizyne Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for IZTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IZTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IZTC vs. The Competition Export to ExcelMetricInvizyne TechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$61.89M$270.30M$5.57B$9.31BDividend YieldN/AN/A4.23%4.03%P/E RatioN/AN/A28.6119.73Price / SalesN/A431.06411.31174.27Price / CashN/A22.4436.0257.96Price / BookN/A9.708.235.67Net IncomeN/A-$110.10M$3.23B$257.79M7 Day Performance-1.01%-0.83%-0.01%0.52%1 Month Performance-22.73%11.85%5.60%8.84%1 Year PerformanceN/A16.17%26.54%14.18% Invizyne Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IZTCInvizyne TechnologiesN/A$9.90+0.9%N/AN/A$61.89MN/A0.0029Gap DownIMMPPrima BioMed1.5025 of 5 stars$1.70+1.2%$7.00+311.8%-20.1%$248.27M$5.14M0.002,021FENCAdherex Technologies2.4629 of 5 stars$8.70+2.7%$13.00+49.4%+33.2%$240.12M$47.54M-17.0610News CoverageEDITEditas Medicine4.2216 of 5 stars$2.86+12.6%$4.70+64.3%-51.0%$239.41M$32.31M-0.94230High Trading VolumeSOPHSOPHiA GENETICS2.6561 of 5 stars$3.56+9.5%$7.00+96.6%-24.6%$237.42M$65.17M-3.56520News CoverageMNPRMonopar Therapeutics2.1692 of 5 stars$38.37+3.1%$60.00+56.4%+1,020.0%$234.82MN/A-11.0310ESPREsperion Therapeutics3.9253 of 5 stars$1.17+5.4%$7.00+498.3%-54.8%$231.89M$332.31M-1.46200Analyst RevisionPRQRProQR Therapeutics2.5221 of 5 stars$2.20+2.8%$8.00+263.6%+34.9%$231.46M$20.46M-6.29180SLRNAcelyrinN/A$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135CGCCanopy Growth0.3233 of 5 stars$1.23+2.5%$2.00+62.6%-84.7%$226.16M$225.65M-0.303,150High Trading VolumeTVGNSemper Paratus Acquisition4.0981 of 5 stars$1.22+1.7%$10.00+719.7%+69.0%$224.35MN/A0.003Gap Down Related Companies and Tools Related Companies Prima BioMed Alternatives Adherex Technologies Alternatives Editas Medicine Alternatives SOPHiA GENETICS Alternatives Monopar Therapeutics Alternatives Esperion Therapeutics Alternatives ProQR Therapeutics Alternatives Acelyrin Alternatives Canopy Growth Alternatives Semper Paratus Acquisition Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IZTC) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invizyne Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invizyne Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IZTC Stock Alerts